Evo Alemao

Evo Alemao

Auto-generated profile, based on publicly available information

Evo Alemao

Bristol-Myers Squibb, Princeton, New Jersey

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2019 in ACR Open Rheumatology
Verified
Journal Article
Open access
PDF file
PKPatti Katz
Patti Katz
SPSofia Pedro
Sofia Pedro
EAEvo Alemao
Evo Alemao
JYJinoos Yazdany
Jinoos Yazdany
MDMaria Dall'ERa
Maria Dall'ERa
KMKaleb Michaud
Kaleb Michaud
Objective: Examinations of Patient‐Reported Outcomes Measurement Information System (PROMIS) measures in adult systemic lupus erythematosus (SLE) have provided support for their cross‐sectional validity in SLE. We estimated responsiveness to change, meaningful changes (minimally important differences [MIDs]), and the patient acceptable symptom state (PASS) for five PROMIS short forms to facilitate longitudinal use and interpretation of PROMIS scales in SLE.Methods: Data from five administrations of PROMIS short forms in the FORWARD SLE cohorts were used. Pearson correlation coefficients were used to assess associations between changes in PROMIS measures and changes in anchor measures for responsiveness analyses. Worse, same, or better groups were defined for each anchor. Differences in PROMIS scores were calculated for each consecutive PROMIS administration; mean changes in PROMIS scores of individuals in the worse, same, and better groups were calculated. Both anchor‐based and distribution‐based methods were used to estimate MIDs. PASS was defined as the 75th‐percentile positive score among those who considered their health to be acceptable or who were somewhat or very satisfied with their health.Results: All PROMIS short forms showed adequate responsiveness to changes in related patient‐reported outcomes. However, only the fatigue and pain interference scales were responsive to self‐reported SLE activity. Taking into account all methods, we estimated MIDs for each scale to be approximately two points. All PASS values were better than the population mean T‐score of 50.Conclusion: These results support use and further study of PROMIS short forms in SLE and should facilitate interpretation of PROMIS scores and changes.

12 January 2017 in Rheumatology
Verified
Journal Article
Open access
PDF file
EAEvo Alemao
Evo Alemao
HCHélène Cawston
Hélène Cawston
FBFrançois Bourhis
François Bourhis
MAMaiwenn Al
Maiwenn Al
MMMaureen Rutten-Van Molken
Maureen Rutten-Van Molken
DSDaniel H. Solomon
Daniel H. Solomon
Objectives. The aims were to compare the performance of cardiovascular risk calculators, Framingham Risk Score (FRS) and QRISK2, in RA and matched non-RA patients and to evaluate whether their performance could be enhanced by the addition of CRP. Methods. We conducted a retrospective analysis, using a clinical practice data set linked to Hospital Episode Statistics (HES) data from the UK. Patients presenting with at least one RA diagnosis code and no prior cardiovascular events were matched to non-RA patients using disease risk scores. The overall performance of the FRS and QRISK2 was compared between cohorts, and assessed with and without CRP in the RA cohort using C-Index, Akaike Information Criterion (AIC) and the net reclassification index (NRI). Results. Four thousand seven hundred and eighty RA patients met the inclusion criteria and were followed for a mean of 3.8 years. The C-Index for the FRS in the non-RA and RA cohort was 0.783 and 0.754 (P < 0.001) and that of the QRISK2 was 0.770 and 0.744 (P < 0.001), respectively. Log[CRP] was positively associated with cardiovascular events, but improvements in the FRS and QRISK2 C-Indices as a result of inclusion of CRP were small, from 0.764 to 0.767 (P = 0.026) for FRS and from 0.764 to 0.765 (P = 0.250) for QRISK2. The NRI was 3.2% (95% CI: −2.8, 5.7%) for FRS and −2.0% (95% CI: −5.8, 4.5%) for QRISK2. Conclusion. The C-Index for the FRS and QRISK2 was significantly better in the non-RA compared with RA patients. The addition of CRP in both equations was not associated with a significant improvement in reclassification based on NRI.

6 June 2019 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
DCDenis Choquette
Denis Choquette
LBLouis Bessette
Louis Bessette
EAEvo Alemao
Evo Alemao
BHBoulos Haraoui
Boulos Haraoui
RPRoelien Postema
Roelien Postema
LCLouis Coupal
Louis Coupal
Treatment persistence is an important consideration when selecting a therapy for chronic conditions such as rheumatoid arthritis (RA). We assessed the long-term persistence of abatacept or a tumor necrosis factor inhibitor (TNFi) following (1) inadequate response to a conventional synthetic disease-modifying antirheumatic drug (first-line biologic agent) and (2) inadequate response to a first biologic DMARD (second-line biologic agent). Data were extracted from the Rhumadata® registry for patients with RA prescribed either abatacept or a TNFi (adalimumab, certolizumab, etanercept, golimumab, or infliximab) who met the study selection criteria. The primary outcome was persistence to abatacept and TNFi treatment, as first- or second-line biologics. Secondary outcomes included the proportion of patients discontinuing therapy, reasons for discontinuation, and predictors of discontinuation. Persistence was defined as the time from initiation to discontinuation of biologic therapy. Baseline characteristics were compared using descriptive statistics; cumulative persistence rates were estimated using Kaplan-Meier methods, compared using the log-rank test. Multivariate Cox proportional hazard models were used to compare the persistence between treatments, controlling for baseline covariates. Overall, 705 patients met the selection criteria for first-line biologic agent initiation (abatacept, n = 92; TNFi, n = 613) and 317 patients met the criteria for second-line biologic agent initiation (abatacept, n = 105; TNFi, n = 212). There were no clinically significant differences in baseline characteristics between the treatments with either first- or second-line biologics. Persistence was similar between the first-line biologic treatments (p = 0.7406) but significantly higher for abatacept compared with TNFi as a second-line biologic (p = 0.0001). Mean (SD) times on first-line biologic abatacept and TNFi use were 4.53 (0.41) and 5.35 (0.20) years, and 4.80 (0.45) and 2.82 (0.24) years, respectively, as second-line biologic agents. The proportion of patients discontinuing abatacept and TNFi in first-line was 51.1% vs. 59.5% (p = 0.1404), respectively. In second-line, it was 57.1% vs. 74.1% (p = 0.0031). The main reasons for stopping both treatments were inefficacy and adverse events. Abatacept and TNFi use demonstrated similar persistence rates at 9 years as a first-line biologic agent. As a second-line biologic agent, abatacept had better persistence rates over a TNFi.

11 February 2019 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
MGMichael D. George
Michael D. George
JBJoshua F. Baker
Joshua F. Baker
KWKevin Winthrop
Kevin Winthrop
EAEvo Alemao
Evo Alemao
LCLang Chen
Lang Chen
JCJeffrey R. Curtis
Jeffrey R. Curtis
Objective: Guidelines recommend withholding biologic therapies before hip and knee arthroplasty, yet evidence to inform optimal timing is limited. The aim of this study was to determine whether withholding abatacept infusions is associated with lower risk of adverse postoperative outcomes.Methods: This retrospective cohort study, which used US Medicare and Truven MarketScan administrative data from January 2006 to September 2015, evaluated adults with rheumatoid arthritis who received intravenous abatacept (precisely dated in claims data) within 6 months of elective primary or revision hip or knee arthroplasty. Propensity weighted analyses using inverse probability weights compared the risk of 30‐day hospitalized infection and 1‐year prosthetic joint infection (PJI) between patients with different abatacept stop timing (time between last infusion and surgery). Secondary analyses evaluated nonurinary hospitalized infections and 30‐day readmissions.Results: After 1,939 surgeries among 1,780 patients, there were 175 hospitalized infections (9.0%), 115 nonurinary hospitalized infections (5.9%), 39 PJIs (2.4/100 person‐years), and 114/1,815 30‐day readmissions (6.3%). There were no significant differences in outcomes with abatacept stop timing <4 weeks (1 dosing interval) versus 4–8 weeks (hospitalized infection odds ratio [OR] 0.93 [95% confidence interval (95% CI) 0.65–1.34]; nonurinary hospitalized infection OR 0.93 [95% CI 0.60–1.44]; PJI hazard ratio 1.29 [95% CI 0.62–2.69]; 30‐day readmission OR 1.00 [95% CI 0.65–1.54]). Similarly, there were no significant differences in outcomes with abatacept stop timing 7.5 mg/day was associated with greater risk of hospitalized infection (OR 2.19 [95% CI 1.28–3.77]) and nonurinary hospitalized infection (OR 2.38 [95% CI 1.22–4.64]).Conclusion: Compared to continuing intravenous abatacept, withholding abatacept for ≥4 weeks (one dosing interval) before surgery was not associated with a lower risk of hospitalized infection, nonurinary hospitalized infection, PJI, or 30‐day readmission.

24 December 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
IPIntan Purnajo
Intan Purnajo
JBJennifer L. Beaumont
Jennifer L. Beaumont
MPMartin Polinsky
Martin Polinsky
EAEvo Alemao
Evo Alemao
MEMatthew J. Everly
Matthew J. Everly
Understanding the correlation between transplant symptoms, health‐related quality of life (HRQoL), and graft outcomes is needed to support patient‐focused drug development and post‐transplant management. A post‐hoc analysis of patient‐reported outcomes from the Phase III belatacept trials was conducted in order to investigate the interrelationship between trajectories of HRQoL, symptom experience, and allograft outcomes. HRQoL and symptom experience were evaluated using Short‐Form 36 Survey (SF‐36) and Modified Transplant Symptom Occurrence and Distress Scale (MTSOSD‐59R), respectively. HRQoL was captured in 831 eligible renal transplant patients at baseline, 12, 24, and 36 months post‐transplant. Following transplantation, patients reported improvements in all SF‐36 subscales compared to baseline. Latent class analysis revealed four trajectories in perceived general health, which were associated with graft failure after adjustment. Compared to patients with good perceived health, patients with fair and poor perceived health had 4.7 (95% CI 1.5‐14.8, p<0.01) and 19.8 (95% CI 5.9‐66.0, p<0.01) times the risk of graft failure, respectively. Using multinomial logistic regression, different sets of symptoms were associated with perceived general health at baseline and 12 months post‐transplant. The study supports monitoring HRQoL and symptom experience to capture each patient’s health perspective, improve drug development, and optimize post‐transplant management.

13 January 2020 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
EAEvo Alemao
Evo Alemao
YBYing Bao
Ying Bao
MWMichael E. Weinblatt
Michael E. Weinblatt
NSNancy Shadick
Nancy Shadick
Objective: Seropositivity for anti–citrullinated protein antibody (ACPA)/rheumatoid factor (RF) in rheumatoid arthritis (RA) is associated with increased overall mortality; however, the association between antibody titers and mortality is not well established. Investigating relationships between antibody titers and mortality may clarify their role in RA pathogenesis. This study was undertaken to evaluate the association of antibody titers with mortality and its modification by disease‐modifying antirheumatic drugs (DMARDs).Methods: Eligible patients with established RA were identified through administrative claims data linked to laboratory results (2005–2016). Patients were categorized by positivity status for ACPA, RF, or both. Patients were further divided into groups by autoantibody titers. DMARD‐exposed patients were categorized into biologic DMARD (bDMARD) and conventional DMARD (cDMARD) subcohorts. Crude mortality rates/1,000 patient‐years and Kaplan‐Meier curves were compared between antibody categories. Adjusted Cox proportional hazards regression and sensitivity (propensity‐matched patients) analyses were conducted.Results: Overall, 53,849 and 79,926 patients had evaluable ACPA and RF status, respectively. For both autoantibodies, mortality rates were significantly higher in seropositive versus seronegative patients (risk increase of 48.0% and 44.0% in ACPA‐ and RF‐positive patients, respectively; P < 0.001 each). Mortality rates were greatest in patients with higher versus lower autoantibody titers (ACPA hazard ratio [HR] 1.60 [95% confidence interval (95% CI]) 1.45–1.76]; RF HR 1.78 [95% CI 1.66–1.91]). In cDMARD‐exposed patients, HRs were higher in seropositive versus seronegative cohorts; in bDMARD‐exposed patients, there was no difference in mortality by serostatus.Conclusion: Elevated ACPA/RF titers were independently associated with increased mortality among patients with RA and persisted in patients treated with cDMARDs but not with bDMARDs.